WuXi STA breaks ground on new Delaware manufacturing facility
European Pharmaceutical Review
AUGUST 17, 2022
The second facility for WuXi STA in the US, Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labelling, storage and distribution services for clinical trial materials and commercial drug products.
Let's personalize your content